Effect of a soluble pseudo-receptor on verotoxin 2-induced toxicity

Journal of Infection and Chemotherapy

Volumn 6, Issue 1, 2000, Pages 21-25

  Takenaga, Mitsuko ^a   Igarashi, Rie ^a   Higaki, Megumu ^a   Nakayama, Toshiaki ^b   Yuki, Koichi ^a   Mizushima, Yutaka ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ASAHI GLASS CO LTD   (Japan)

Author keywords

Globotrisylceramide (Gb3); Lyso Gb3; O 157; Vero cell; Verotoxin 2 (VT2)

Indexed keywords

GLOBOTRIAOSYLCERAMIDE; LYSO GB3; UNCLASSIFIED DRUG; VEROTOXIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; NONHUMAN; RECEPTOR AFFINITY; THROMBOCYTOPENIA; VERO CELL;

EID: 0034063902     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560050044     Document Type: Article

References (17)

1. Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, Grandis SD, et al. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem 1987;262: 8834-9.
2. Lingwood CA. Verotoxins and their glycolipid receptors. Adv Lipid Res 1993;25:189-211.
3. Waddell T, Cohen A, Lingwood CA. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc Natl Acad Sci USA 1990;87:7898-901.
4. Armstrong GD, Fodor E, Vanmaele R. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J Infect Dis 1991;164:1160-7.
5. Armstrong GD, Rowe PC, Goodyer P, Orrbine E, Klassen TP, Wells G, et al. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis 1995;171:1042-5.
6. Heerze LD, Kelm MA, Talbot JA, Armstrong GD. Oligosaccharide sequences attached to an inert support (Synsorb) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis. J Infect Dis 1994;169:1291-6.
7. Schmidt RR, Zimmermann P. Synthesis of D-erythro-sphingosines. Tetrahedron Lett 1986;27:481-4.
8. Nicolaou KC, Caulfield T, Kataoka H, Kumazawa T. A practical and enantioselective synthesis of glycosphingolipids and related compounds. Total synthesis of globotriaosylceramide (Gb3). J Am Chem Soc 1988;110:7910-2.
9. Basta M, Karmall M, Lingwood C. Sensitive receptor-specified enzyme-linked immunosorbent assay for Escherichia coli verocytotoxin. J Clin Microbiol 1989;27:1617-22.
10. Boulanger J, Petric M, Linwood C, Law H, Roscoe M, Karmali M. Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verotoxin 1. J Clin Microbiol 1990;28:2830-3.
11. Pellizzari A, Pang H, Lingwood CA. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 1992;31:1363-70.
12. Volti SL, Giacomo CD, Garozzo R, Campisi A, Mollica F, Vanella A. Impaired antioxidant defense mechanisms in two children with hemolytic-uremic syndrome. Ren Fail 1993;15:523-8.
13. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985;151:775-82.
14. Ito T, Akino E, Hiramatsu K. Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157:H7 enteritis; effect of various antibiotics on extracellular release of verotoxin (in Japanese). Kansenshogaku Zasshi J Jpn Assoc Infect Dis 1997;71:130-5.
15. Kohsaka T, Tagawa M, Suzuki T, Ito H. The old and new problems of the antibiotics treatment in hemorrhagic enterocolitis and hemolytic uremic syndrome, according to Japanese epidemiological studies (in Japanese). Nippon Rinsho Jpn J Clin Med 1997;55:706-14.
16. Takaki Y, Makishita A, Goto M, Motomatsu T, Yoshihara T. An old female case of vero-cytotoxin-producing Escherichia coli O-157:H7 infection (in Japanese). Fukuoka Igaku Zasshi Fukuoka acta medica 1997;88:128-31.
17. Fujii J, Yoshida S. Brain lesions in rabbits given an intravenous injection of verotoxin 2 and protection by anti-VT2 antibody (in Japanese). Nippon Rinsho Jpn J Clin Med 1997;55(3):736-40.